当前位置:首页 - 行情中心 - 上海医药(601607) - 财务分析 - 现金流量表

上海医药

(601607)

  

流通市值:366.79亿  总市值:702.36亿
流通股本:19.37亿   总股本:37.08亿

现金流量表

报告期2024-12-312024-09-302024-06-302024-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金301,138,074,959.71216,241,126,794.79143,040,840,673.3566,602,368,417.66
收到的税费返还157,075,769.86161,365,821.57109,651,206.4534,893,033.21
收到其他与经营活动有关的现金3,355,474,894.373,014,000,050.911,692,189,000.811,174,472,290.3
经营活动现金流入的平衡项目0000
经营活动现金流入小计304,650,625,623.94219,416,492,667.27144,842,680,880.6167,811,733,741.17
购买商品、接受劳务支付的现金268,134,361,085.34192,621,520,661.57127,982,487,400.7464,511,143,499.18
支付给职工以及为职工支付的现金10,639,199,652.276,829,300,693.725,633,875,615.092,640,098,105.52
支付的各项税费7,327,044,163.215,770,527,692.33,763,146,129.922,067,750,418.44
支付其他与经营活动有关的现金12,722,762,991.7911,412,179,163.426,947,868,351.834,066,341,430.67
经营活动现金流出的平衡项目0000
经营活动现金流出小计298,823,367,892.61216,633,528,211.01144,327,377,497.5873,285,333,453.81
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额5,827,257,731.332,782,964,456.26515,303,383.03-5,473,599,712.64
二、投资活动产生的现金流量:
收回投资收到的现金47,809,428,496.4117,454,567,00011,350,000,00010,050,000,000
取得投资收益收到的现金1,346,951,721.68971,322,262.61701,767,577.55120,895,726.03
处置固定资产、无形资产和其他长期资产收回的现金净额244,660,546.13159,079,166.98138,689,186.29815,734.76
处置子公司及其他营业单位收到的现金净额-12,364,306.65-11,514,306.65
收到的其他与投资活动有关的现金1,032,193,865.93756,787,587.49705,238,031.66348,516,368.37
投资活动现金流入的平衡项目0000
投资活动现金流入小计50,433,234,630.1519,354,120,323.7312,895,694,795.510,531,742,135.81
购建固定资产、无形资产和其他长期资产支付的现金2,400,874,817.191,835,291,094.21,393,196,297.47871,616,895.89
投资支付的现金45,933,887,00015,857,397,0008,400,000,0007,100,000,000
取得子公司及其他营业单位支付的现金85,292,225.3493,692,695.483,508,582.824,034,930.28
支付其他与投资活动有关的现金1,597,200,887.931,209,757,790.34985,812,200714,357,790.97
投资活动现金流出的平衡项目0000
投资活动现金流出小计50,017,254,930.4618,996,138,579.9410,862,517,080.298,690,009,617.14
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额415,979,699.69357,981,743.792,033,177,715.211,841,732,518.67
三、筹资活动产生的现金流量:
吸收投资收到的现金86,196,122.618,315,022.813,743,691.91-
取得借款收到的现金61,928,229,561.8545,513,265,721.3535,603,636,632.0518,435,199,786.22
发行债券收到的现金11,997,222,500.018,997,610,000.015,998,726,666.672,999,522,500
收到其他与筹资活动有关的现金137,374,213.51654,648,042.46126,620,00086,542,631.35
筹资活动现金流入平衡项目0000
筹资活动现金流入小计74,149,022,397.9755,183,838,786.6341,732,726,990.6321,521,264,917.57
偿还债务支付的现金70,102,029,449.9450,540,691,452.4135,828,520,541.9717,414,048,741.02
分配股利、利润或偿付利息支付的现金4,309,892,169.513,431,566,587.41,102,901,126.35657,029,889.33
其中:子公司支付给少数股东的股利、利润706,216,464.59310,114,905.19151,114,751.2897,808,995.85
支付其他与筹资活动有关的现金1,601,031,157.181,074,804,786.251,038,205,257.32199,933,738.62
筹资活动现金流出平衡项目0000
筹资活动现金流出小计76,012,952,776.6355,047,062,826.0637,969,626,925.6418,271,012,368.97
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-1,863,930,378.66136,775,960.573,763,100,064.993,250,252,548.6
四、汇率变动对现金及现金等价物的影响2,156,741.31-22,872,683.73-8,187,361.977,736,229.48
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额4,381,463,793.673,254,849,476.896,303,393,801.26-373,878,415.89
加:期初现金及现金等价物余额27,499,809,001.227,499,809,001.227,499,809,001.227,499,809,001.2
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额31,881,272,794.8730,754,658,478.0933,803,202,802.4627,125,930,585.31
补充资料:
净利润5,870,011,314.88-3,597,363,036.62-
资产减值准备614,373,564.47-36,526,101.71-
固定资产和投资性房地产折旧1,294,305,848.92-604,856,357.33-
无形资产摊销399,940,491.39-198,802,167.05-
长期待摊费用摊销191,100,283.87-85,945,173.34-
处置固定资产、无形资产和其他长期资产的损失-187,967,998.85--139,310,426.73-
公允价值变动损失-203,853,796.87--114,288,629.44-
财务费用1,837,342,811.14-915,719,792.37-
投资损失-593,000,866.77--342,020,635.74-
递延所得税-110,038,272.1--69,992,479.12-
其中:递延所得税资产减少89,329,045.05--38,384,896.92-
递延所得税负债增加-199,367,317.15--31,607,582.2-
存货的减少-2,297,647,988.62-1,335,453,749.85-
经营性应收项目的减少-4,041,023,805.03--7,868,733,874.13-
经营性应付项目的增加2,103,001,583.06-1,622,348,664.67-
现金的期末余额31,881,272,794.87-33,803,202,802.46-
减:现金的期初余额27,499,809,001.2-27,499,809,001.2-
公告日期2025-03-282024-10-302024-08-272024-04-27
审计意见(境内)标准无保留意见
TOP↑